drugset / Trial / NCT05127135
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
Phase 1
Unknown
30 enrolled
Fundamenta Therapeutics, Ltd.
The First Affiliated Hospital of University of Science and Technology of China · collab
NaSequentialOpen-labelTreatment
Summary
This is a single dose escalation study to evaluate the safety and clinical activity of ThisCART7(Allogeneic CAR-T targeting CD7) in patients with refractory or relapsed CD7 positive T cell malignancies.
Timeline
- Start
- 2020-01-22
- Primary completion
- 2023-01-24
- Completion
- 2023-12-24